Author:
Atzpodien J, ,Schmitt E,Gertenbach U,Fornara P,Heynemann H,Maskow A,Ecke M,Wöltjen H H,Jentsch H,Wieland W,Wandert T,Reitz M
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H (1995) Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174–177
2. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, von Jürgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-α and 5-FU vs tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85(8): 1130–1136
3. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Interleukin-2- and interferon-alpha2a-based immuno-chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized Trial of The German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22(7): 1188–1194
4. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group Randomized Trial. J Clin Oncol 21(16): 3133–3140
5. Dutcher JP, Logan T, Gordon M, Sosman J, Weis G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M (2000) Pase II trial of interleukin-2, interferon-alfa, and 5-fluorouracil in metastatic renal cell cancer: a Cytokine Working Group Study. Clin Cancer Res 6: 3442–3450
Cited by
157 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献